Inflammation and Oral Cancer: An Update Review on Targeted Therapies

Journal of Contemporary Dental Practice

Volumn 16, Issue 7, 2015, Pages 595-602

  Sarode, Gargi S ^a   Sarode, Sachin C ^a   Patil, Anuprita ^b   Anand, Rahul ^a   Patil, Shankar Gouda ^c   Rao, Roopa S ^c   Augustine, Dominic ^c  

^a DR D Y PATIL DENTAL COLLEGE AND HOSPITAL   (India)

^b EK 2 Emirates building   (United Arab Emirates)

^c M S RAMAIAH UNIVERSITY OF APPLIED SCIENCES   (India)

Author keywords

AP 1; Cancer associated inflammation; Connective tissue growth factor; COX 2; Epidermal growth factor receptor; MAP kinase; NF B; Oral cancer; p38 ; PPAR ; RhoC; STAT 3

Indexed keywords

ANTIINFLAMMATORY AGENT;

CARCINOGENESIS; DRUG EFFECT; HUMAN; INFLAMMATION; MOLECULARLY TARGETED THERAPY; MOUTH TUMOR; PATHOPHYSIOLOGY; PROCEDURES; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA;

ANTI-INFLAMMATORY AGENTS; CARCINOGENESIS; CARCINOMA, SQUAMOUS CELL; HUMANS; INFLAMMATION; MOLECULAR TARGETED THERAPY; MOUTH NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84971434394     PISSN: None     EISSN: 15263711     Source Type: Journal    
DOI: 10.5005/JP-JOURNALS-10024-1727     Document Type: Article

References (75)

1. 1. Vokes EE, Weichselbaum RR, Lippman SM, Hong WK. Head and neck cancer. N Engl J Med 1993;328(3):184-194.
2. 2. Boyle P, Macfarlane GJ, Zheng T, Maisonneuve P, Evstifeeva T, Scully C. Recent advances in epidemiology of head and neck cancer. Curr Opin Oncol 1992;4(3):471-477.
3. 3. Babu KG. Oral cancers in India. Semin Oncol 2001;28(2): 169-173.
4. 4. Sarode SC, Sarode GS, Karmarkar S. Early detection of oral cancer: detector lies within. Oral Oncol 2012;48(3):193-194.
5. 5. Sarode SC, Sarode GS, Karmarkar S, Kalele K. OP(Oral Pathologist)inion matters. Oral Oncol 2012;48(11):e47-48.
6. 6. Sarode SC, Sarode GS, Patil A. Criteria to define true second primary oral squamous cell carcinoma. Oral Oncol 2010; 46(11):834.
7. 7. Song JI, Grandis JR. STAT signaling in head and neck cancer. Oncogene 2000;19(15):2489-2495.
8. 8. Dhooge IJ, De Vos M, Van Cauwenberge PB. Multiple primary malignant tumors in patients with head and neck cancer: results of a prospective study and future perspectives. Laryngoscope 1998;108(2):250-256.
9. 9. Todd R, Donoff RB, Wong DT. The molecular biology of oral carcinogenesis: toward a tumor progression model. J Oral Maxillofac Surg 1997;55(6):613-623.
10. 10. Williams HK. Molecular pathogenesis of oral squamous carcinoma. Mol Pathol 2000;53(4):165-172.
11. 11. Loro LL, Vintermyr OK, Johannessen AC. Cell death regulation in oral squamous cell carcinoma: methodological considerations and clinical significance. J Oral Pathol Med 2003;32(3):125-138.
12. 12. Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 2009;30(7): 1073-1081.
13. 13. Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 2005;7(3):211-217.
14. 14. Feller L, Altini M, Lemmer J. Inflammation in the context of oral cancer. Oral Oncol 2013;49(9):887-892.
15. 15. Sarode SC, Sarode GS, Karmarkar S, Tupkari JV. A new classification for potentially malignant disorders of the oral cavity. Oral Oncol 2011;47(9):920-921.
16. 16. Sarode SC, Sarode GS, Tupkari JV. Oral potentially malignant disorders: precising the definition. Oral Oncol 2012;48(9): 759-760.
17. 17. Sarode SC, Sarode GS, Karmarkar S, Tupkari JV. Oral (mucosal) potentially malignant disorders. Oral Oncol 2012;48(10):e35-36.
18. 18. Tokuyama H, Hayashi K, Matsuda H, Kubota E, Honda M, Okubo K, Ozawa Y, Saruta T. Distinct role of intrarenal cyclooxygenase-1/2 in chronic unilateral renal ischemia. Nephron 2002;92(1):183-191.
19. 19. Sonoda R, Naomoto Y, Shirakawa Y, Fujiwara Y, Yamatsuji T, Noma K, Tanabe S, Takaoka M, Gunduz M, Tsujigiwa H, et al. Preferential up-regulation of heparanase and cyclooxygenase-2 in carcinogenesis of Barrett’s oesophagus and intestinal-type gastric carcinoma. Histopathology 2010;57(1):90-100.
20. 20. Yao L, Liu F, Hong L, Sun L, Liang S, Wu K, Fan D. The function and mechanism of COX-2 in angiogenesis of gastric cancer cells. J Exp Clin Cancer Res 2011;30:13.
21. 21. Ristimäki A, Honkanen N, Jänkälä H, Sipponen P, Härkönen M. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res 1997;57(7):1276-1280.
22. 22. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010;140(6):883-899.
23. 23. Wang D, Dubois RN. The role of COX-2 in intestinal inflammation and colorectal cancer. Oncogene 2010;29(6):781-788.
24. 24. Chen Z, Zhang X, Li M, Wang Z, Wieand HS, Grandis JR, Shin DM. Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck. Clin Cancer Res 2004;10(17):5930-5939.
25. 25. Nathan CO, Leskov IL, Lin M, Abreo FW, Shi R, Hartman GH, Glass J. COX-2 expression in dysplasia of the head and neck: correlation with elF4E. Cancer 2001;92(7):1888-1895.
26. 26. Wirth LJ, Krane JF, Li Y, Othus M, Moran AE, Dorfman DM, Norris CM Jr, Goguen L, Posner MR, Haddad RI, et al. A pilot surrogate endpoint biomarker study of celecoxib in oral premalignant lesions. Cancer Prev Res (Phila) 2008;1(5): 339-348.
27. 27. Papadimitrakopoulou VA, William WN Jr, Dannenberg AJ, Lippman SM, Lee JJ, Ondrey FG, Peterson DE, Feng L, Atwell A, El-Naggar AK, et al. Pilot randomized phase II study of celecoxib in oral premalignant lesions. Clin Cancer Res 2008;14(7):2095-2101.
28. 28. Ondrey FG, Juhn SK, Adams GL. Inhibition of head and neck tumor cell growth with arachidonic acid metabolism inhibition. Laryngoscope 1996;106(2):129-134.
29. 29. Moral M, Paramio JM. Akt pathway as a target for therapeutic intervention in HNSCC. Histol Histopathol 2008; 23(10): 1269-1278.
30. 30. Zhu J, Huang JW, Tseng PH, Yang YT, Fowble J, Shiau CW, Shaw YJ, Kulp SK, Chen CS. From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositidedependent protein kinase-1 inhibitors. Cancer Res 2004;64(12):4309-4318.
31. 31. Kucab JE, Lee C, Chen CS, Zhu J, Gilks CB, Cheang M, Huntsman D, Yorida E, Emerman J, Pollak M, et al. Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumours. Breast Cancer Res 2005;7(5):R 796-807.
32. 32. Zhang X, Chen ZG, Choe MS, Lin Y, Sun SY, Wieand HS, Shin HJ, Chen A, Khuri FR, Shin DM. Tumor growth inhibition by simultaneously blocking epidermal growth factor receptor and cyclooxygenase-2 in a xenograft model. Clin Cancer Res 2005;11(17):6261-6269.
33. 33. Choe MS, Zhang X, Shin HJ, Shin DM, Chen ZG. Interaction between epidermal growth factor receptorand cyclooxygenase 2-mediated pathways and its implications for the chemoprevention of head and neck cancer. Mol Cancer Ther 2005;4(9):1448-1455.
34. 34. Saba N, Hurwitz SJ, Kono S, Yang CS, Zhao Y, Chen Z, Sica G, Müller S, Moreno-Williams R, Lewis M, et al. Chemoprevention of Head and Neck Cancer with Celecoxib and Erlotinib: Results of a Phase 1b and Pharmacokinetic Study. Cancer Prev Res (Phila) 2014 Mar;7(3):283-291.
35. 35. Chuang JY, Yang WY, Lai CH, Lin CD, Tsai MH, Tang CH. CTGF inhibits cell motility and COX-2 expression in oral cancer cells. Int Immunopharmacol 2011;11(8):948-954.
36. 36. Perbal B. CCN proteins: multifunctional signalling regulators. Lancet 2004;363(9402):62-64.
37. 37. Pelech SL, Sanghera JS. MAP kinases: charting the regulatory pathways. Science 1992;257(5075):1355-1356.
38. 38. Pedraza-Alva G, Koulnis M, Charland C, Thornton T, Clements JL, Schlissel MS, Rincon M. Activation of p38 MAP kinase by DNA double-strand breaks in V(D)J recombination induces a G2/M cell cycle checkpoint. EMBO J 2006;25(4):763-773.
39. 39. Gill K, Mohanti BK, Ashraf MS, Singh AK, Dey S. Quantification of p38alphaMAP kinase: a prognostic marker in HNSCC with respect to radiation therapy. Clin Chim Acta 2012;413(1):219-225.
40. 40. Gill K, Singh AK, Kapoor V, Nigam L, Kumar R, Holla P, Das SN, Yadav S, Subbarao N, Mohanti BK, et al. Development of peptide inhibitor as a therapeutic agent against head and neck squamous cell carcinoma (HNSCC) targeting p38α MAP kinase. Biochim Biophys Acta 2013;1830(3):2763-2769.
41. 41. Buettner R, Mora LB, Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 2002;8(4):945-954.
42. 42. Yu H, Jove R. The STATs of cancer–new molecular targets come of age. Nat Rev Cancer 2004;4(2):97-105.
43. 43. Fan Y, Mao R, Yang J. NF-κB and STAT3 signaling pathways collaboratively link inflammation to cancer. Protein Cell 2013; 4(3):176-185.
44. 44. Vander Broek R, Snow GE, Chen Z, Van Waes C. Chemopre-vention of head and neck squamous cell carcinoma through inhibition of NF-κB signaling. Oral Oncol 2014 Oct;50(10): 930-941.
45. 45. Shishodia S, Aggarwal BB. Guggulsterone inhibits NF-kappa B and Ikappa Balpha kinase activation, suppresses expression of antiapoptotic gene products, and enhances apoptosis. J Biol Chem 2004;279(45):47148-47158.
46. 46. Singh SV, Zeng Y, Xiao D, Vogel VG, Nelson JB, Dhir R, Tripathi YB. Caspase-dependent apoptosis induction by guggulsterone, a constituent of Ayurvedic medicinal plant Commiphora mukul, in PC-3 human prostate cancer cells is mediated by Bax and Bak. Mol Cancer Ther 2005;4(11): 1747-1754.
47. 47. Samudio I, Konopleva M, Safe S, McQueen T, Andreeff M. Guggulsterones induce apoptosis and differentiation in acute myeloid leukemia: identification of isomer-specific antileukemic activities of the pregnadienedione structure. Mol Cancer Ther 2005;4(12):1982-1992.
48. 48. Shishodia S, Sethi G, Ahn KS, Aggarwal BB. Guggulsterone inhibits tumor cell proliferation, induces S-phase arrest, and promotes apoptosis through activation of c-Jun N-terminal kinase, suppression of Akt pathway, and downregulation of antiapoptotic gene products. Biochem Pharmacol 2007;74(1):118-130.
49. 49. Singh SV, Choi S, Zeng Y, Hahm ER, Xiao D. Guggulsteroneinduced apoptosis in human prostate cancer cells is caused by reactive oxygen intermediate dependent activation of c-Jun NH2-terminal kinase. Cancer Res 2007;67(15):7439-7449.
50. 50. An MJ, Cheon JH, Kim SW, Kim ES, Kim TI, Kim WH. Guggulsterone induces apoptosis in colon cancer cells and inhibits tumor growth in murine colorectal cancer xenografts. Cancer Lett 2009;279(1):93-100.
51. 51. Ahn KS, Sethi G, Sung B, Goel A, Ralhan R, Aggarwal BB. Guggulsterone, a farnesoid X receptor antagonist, inhibits constitutive and inducible STAT3 activation through induction of a protein tyrosine phosphatase SHP-1. Cancer Res 2008;68(11):4406-4415.
52. 52. Leeman-Neill RJ, Wheeler SE, Singh SV, Thomas SM, Seethala RR, Neill DB, Panahandeh MC, Hahm ER, Joyce SC, et al. Guggulsterone enhances head and neck cancer therapies via inhibition of signal transducer and activator of transcription-3. Carcinogenesis 2009;30(11):1848-1856.
53. 53. Macha MA, Matta A, Chauhan SS, Siu KW, Ralhan R. Guggulsterone (GS) inhibits smokeless tobacco and nicotineinduced NF-κB and STAT3 pathways in head and neck cancer cells. Carcinogenesis 2011;32(3):368-380.
54. 54. Macha MA, Matta A, Chauhan SS, Siu KW, Ralhan R. Guggulsterone targets smokeless tobacco induced PI3K/Akt pathway in head and neck cancer cells. PLoS One 2011;6(2):e14728.
55. 55. Sahai E, Marshall CJ. ROCK and Dia have opposing effects on adherens junctions downstream of Rho. Nat Cell Biol 2002;4 (6):408-415.
56. 56. van Golen KL, Wu ZF, Qiao XT, Bao LW, Merajver SD. RhoC GT Pase, a novel transforming oncogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype. Cancer Res 2000;60(20):5832-5838.
57. 57. Kleer CG, Zhang Y, Pan Q, Gallagher G, Wu M, Wu ZF, Merajver SD. WISP3 and RhoC guanosine triphosphatase cooperate in the development of inflammatory breast cancer. Breast Cancer Res 2004;6(1):R110-115.
58. 58. Schmalbach CE, Chepeha DB, Giordano TJ, Rubin MA, Teknos TN, Bradford CR, Wolf GT, Kuick R, Misek DE, Trask DK, et al. Molecular profiling and the identification of genes associated with metastatic oral cavity/pharynx squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2004;130(3):295-302.
59. 59. van Golen KL, Wu ZF, Qiao XT, Bao L, Merajver SD. RhoC GTPase overexpression modulates induction of angiogenic factors in breast cells. Neoplasia 2000;2(5):418-425.
60. 60. Kleer CG, Teknos TN, Islam M, Marcus B, Lee JS, Pan Q, Merajver SD. RhoC GTPase expression as a potential marker of lymph node metastasis in squamous cell carcinomas of the head and neck. Clin Cancer Res 2006;12(15):4485-4490.
61. 61. Islam M, Sharma S, Kumar B, Teknos TN. Atorvastatin inhibits RhoC function and limits head and neck cancer metastasis. Oral Oncol 2013;49(8):778-786.
62. 62. Collisson EA, Kleer C, Wu M, De A, Gambhir SS, Merajver SD, Kolodney MS. Atorvastatin prevents RhoC isoprenylation, invasion, and metastasis in human melanoma cells. Mol Cancer Ther 2003;2(10):941-948.
63. 63. Floyd ZE, Stephens JM. Controlling a master switch of adipocyte development and insulin sensitivity: covalent modifications of PPARgamma. Biochim Biophys Acta 2012;1822(7):1090-1095.
64. 64. Glass CK, Saijo K. Nuclear receptor transrepression pathways that regulate inflammation in macrophages and T cells. Nat Rev Immunol 2010;10:365-376.
65. 65. Peters JM, Shah YM, Gonzalez FJ. The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention. Nat Rev Cancer 2012;12(3):181-195.
66. 66. Bren-Mattison Y, Meyer AM, Van Putten V, Li H, Kuhn K, Stearman R, Weiser-Evans M, Winn RA, Heasley LE, Nemenoff RA. Antitumorigenic effects of peroxisome proliferator-activated receptor-gamma in non-small-cell lung cancer cells are mediated by suppression of cyclooxygenase-2 via inhibition of nuclear factor-kappaB. Mol Pharmacol 2008; 73(3):709-717.
67. 67. Yoshida K, Hirose Y, Tanaka T, Yamada Y, Kuno T, Kohno H, Katayama M, Qiao Z, Sakata K, Sugie S, et al. Inhibitory effects of troglitazone, a peroxisome proliferator-activated receptor gamma ligand, in rat tongue carcinogenesis initiated with 4-nitroquinoline 1-oxide. Cancer Sci 2003;94(4):365-371.
68. 68. Govindarajan R, Siegel ER, Simmons DL, Lang NP. Thiazolidinedione (TZD) exposure and risk of squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol 2007;25(18 Suppl):1511.
69. 69. Neumann A, Weill A, Ricordeau P, Fagot JP, Alla F, Allemand H. Pioglitazone and risk of bladder cancer among diabetic patients in France: a opulation based cohort study. Diabetologia 2012;55(7):1953-1962.
70. 70. Kivisto KT, Kroemer HK, Eichelbaum M. The role of human cytochrome P450 enzymes in the metabolism of anticancer agents—implications for drug interactions. Br J Clin Pharmacol 1995;40(6):523-530.
71. 71. Rivory LP, Slaviero KA, Clarke SJ. Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acutephase response. Br J Cancer 2002;87(3):277-280.
72. 72. Slaviero KA, Clarke SJ, Rivory LP. Inflammatory response: An unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy. Lancet Oncol 2003;4(4):224-232.
73. 73. Assenat E, Gerbal-Chaloin S, Larrey D, Saric J, Fabre JM, Maurel P, Vilarem MJ, Pascussi JM. Interleukin 1β inhibits CAR induced expression of hepatic genes involved in drug and bilurubin clearance. Hepatology 2004;40(4):951-960.
74. 74. Morgan ET, Li-Masters T, Cheng PY. Mechanisms of cytochrome P450 regulation by inflammatory mediators. Toxicology 2002;181-182:207-210.
75. 75. Pascussi JM, Gerbal-Chaloin S, Pichard-Garcia L, Daujat M, Fabre JM, Maurel P, Vilarem MJ. Interleukin-6 negatively regulates the expression of pregnane X receptor and constitutively activated receptor in primary human hepatocytes. Biochem Biophys Res Commun 2000;274(3):707-713.